Finland is experiencing issues with the availability of both new and established medications, raising concerns about healthcare access. The problem extends beyond recently developed drugs, with older, previously readily available medicines also disappearing from the market. This scarcity impacts patient care and necessitates a reassessment of how pharmaceutical value is measured. Experts emphasize that a single metric cannot adequately evaluate the worth of a drug, considering factors beyond purely economic considerations. The situation highlights vulnerabilities in the pharmaceutical supply chain and the importance of diversified sourcing. Addressing these challenges requires a comprehensive approach to ensure consistent access to essential medicines for the population. This growing trend threatens consistent patient treatment and warrants urgent attention from healthcare authorities.